WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; and drug discovery services to pharmaceutical and biotech customers. In addition, the company offers consulting services for combinatorial chemistry and pharmaceuticals; and develops computer software and databases. Further, it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| 6.81 | |
| 6.81 | |
| - | |
| 6.81 | |
| 6.81 | |
| 3.3751-8.2778 | |
| 21 861 M | |
| 17.9211 | |
| 387 M | |
| 38 501 M | |
| 0.1102 | |
| 0.0195 | |
| 0.813 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
By Karen Freifeld (Reuters) -The U.S. House of Representatives passed a bill on Monday that aims to restrict business with China's WuXi AppTec, BGI and several other biotech companies on national sec...
Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commerci...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
